Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high dose melphalan

During a 5 year period, 64 children with advanced stage malignant solid tumours have been treated with high dose melphalan (140‐220 mg/m2) combined with non‐cryopreserved autologous marrow transplantation. All children developed a profound neutropenia and thrombocytopenia following high dose melphalan. Both the duration of neutropenia (median l1d) and the duration of thrombocytopenia (median 18 d) were related to the nucleated cell count of the reinfused marrow but neither appeared to be affected by the dose of melphalan. This suggests that the initial recovery of the peripheral blood count results from the engrafted autologous marrow. We conclude that autologous marrow transplantation accelerates haemopoietic recovery in children with solid tumours treated with high dose melphalan.

[1]  J. Kemshead,et al.  REMOVAL OF NEUROBLASTOMA CELLS FROM BONE MARROW WITH MONOCLONAL ANTIBODIES CONJUGATED TO MAGNETIC MICROSPHERES , 1984, The Lancet.

[2]  T. Mcelwain,et al.  Childhood rhabdomyosarcoma: experience of the Children's Solid Tumour Group. , 1983, British Journal of Cancer.

[3]  I. Smith,et al.  AUTOLOGOUS BONE MARROW RESCUE IS UNNECESSARY AFTER VERY-HIGH-DOSE CYCLOPHOSPHAMIDE , 1983, The Lancet.

[4]  J. Graham-Pole,et al.  High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. , 1982, British Journal of Cancer.

[5]  V. Courtenay,et al.  Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy. , 1980, British Journal of Cancer.

[6]  D. Hedley,et al.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. , 1979, British Journal of Cancer.

[7]  T. Mcelwain,et al.  Cyclophosphamide pretreatment reduces the toxic effect of high dose melphalan on intestinal epithelium in sheep. , 1978, European journal of cancer.

[8]  J. Minna,et al.  Intensive chemotherapy of small cell bronchogenic carcinoma. , 1977, Cancer treatment reports.

[9]  M. Hreshchyshyn.  Single-drug therapy in ovarian cancer. , 1974, Obstetrical & gynecological survey.

[10]  M. Hreshchyshyn.  Single-drug therapy in ovarian cancer: Factors influencing response , 1973 .

[11]  D. Bergsagel,et al.  Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. , 1972, Canadian Medical Association journal.

[12]  P. Neiman,et al.  High‐dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow , 1972 .

[13]  D. Bergsagel.  An assessment of massive-dose chemotherapy of malignant disease. , 1971, Canadian Medical Association journal.

[14]  W. R. Bruce,et al.  Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. , 1967, Journal of the National Cancer Institute.

[15]  G. Pack,et al.  Treatment of disseminated melanoma with phenylalanine mustard (melphelan) and autogenous bone marrow transplants. , 1962, Surgery.

[16]  P. Clifford,et al.  Nitrogen-mustard therapy combined with autologous marrow infusion. , 1961, Lancet.

[17]  W. Dameshek,et al.  Autologous bone marrow infusion as an adjunct in therapy of malignant disease. , 1959, Blood.

[18]  J. G. Humble,et al.  Disseminated malignant melanoma: response to treatment by massive dosage of a cytotoxic agent combined with autogenous marrow replacement. , 1959, Lancet.